Al-Obaidi M K, Philippou H, Stubbs P J, Adami A, Amersey R, Noble M M, Lane D A
National Heart and Lung Institute, Cardiology and Haematology Departments, Charing Cross Campus, Imperial College School of Medicine, London, UK.
Circulation. 2000 Feb 1;101(4):372-7. doi: 10.1161/01.cir.101.4.372.
It has been suggested by clinical, epidemiological, and experimental in vitro studies that homocysteine potentiates thrombin generation. This prothrombotic effect however has not previously been demonstrated in patients presenting with acute coronary syndromes (ACS).
Patients with ACS (n =117) presenting with confirmed acute myocardial infarction (MI) (n =57) or unstable angina pectoris (UAP) (n =60) were consecutively recruited together with patients (n =18) in whom the presenting chest pain was not of cardiac origin (NCP), included as controls. Plasma samples were collected on admission and before clinical intervention. Homocysteine was assayed by high performance liquid chromatography, and both Factor VIIa and prothrombin fragment F1+2 were analyzed by ELISA. There were significant elevations in F1+2 in MI (P<0.001) and UAP (P=0.003), and modest elevations in Factor VIIa in UAP (P<0.05) compared with NCP but no differences in homocysteine levels among those groups. On dividing patients with ACS into quartiles of homocysteine, there was a stepwise increase in F1+2 (P<0.0001) and of Factor VIIa (P<0.05). There were significant correlations in ACS between homocysteine and F1+2 (r=0.46, P<0.0001), homocysteine and Factor VIIa (r=0.24, P<0.01), and F1+2 and Factor VIIa (r=0.41, P<0.0001). There was no correlation between homocysteine and either F1+2 (r=-0.15, P=0.57) or Factor VIIa (r=0. 22, P=0.37) in the NCP patients.
Elevated plasma homocysteine is associated with and may cause elevated Factor VIIa and thrombin generation in patients presenting with ACS. These findings suggest an explanation for the prothrombotic effect of homocysteine in ACS.
临床、流行病学及体外实验研究表明,同型半胱氨酸可增强凝血酶生成。然而,此前急性冠脉综合征(ACS)患者中尚未证实这种促血栓形成作用。
连续纳入117例ACS患者,其中确诊急性心肌梗死(MI)患者57例,不稳定型心绞痛(UAP)患者60例,同时纳入18例胸痛非心脏源性(NCP)患者作为对照。入院时及临床干预前采集血浆样本。采用高效液相色谱法检测同型半胱氨酸,采用酶联免疫吸附测定法分析凝血因子Ⅶa和凝血酶原片段F1+2。与NCP组相比,MI组(P<0.001)和UAP组(P=0.003)的F1+2显著升高,UAP组凝血因子Ⅶa轻度升高(P<0.05),但各组间同型半胱氨酸水平无差异。将ACS患者按同型半胱氨酸四分位数分组后,F1+2(P<0.0001)和凝血因子Ⅶa(P<0.05)呈逐步升高趋势。ACS患者中,同型半胱氨酸与F1+2(r=0.46,P<0.0001)、同型半胱氨酸与凝血因子Ⅶa(r=0.24,P<0.01)、F1+2与凝血因子Ⅶa(r=0.41,P<0.0001)之间均存在显著相关性。NCP患者中,同型半胱氨酸与F1+2(r=-0.15,P=0.57)或凝血因子Ⅶa(r=0.22,P=0.37)之间无相关性。
血浆同型半胱氨酸升高与ACS患者凝血因子Ⅶa升高及凝血酶生成增加相关,且可能导致后者发生。这些发现为同型半胱氨酸在ACS中的促血栓形成作用提供了解释。